Press Releases

Shockwave Medical Reports Second Quarter 2023 Financial Results

SANTA CLARA, Calif., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, today reported financial results for the three months ended June 30, 2023.

Recent Highlights

  • Recognized revenue of $180.2 million for the second quarter of 2023, representing an increase of 49% from the same period in 2022
  • As part of the Fiscal Year 2024 Medicare Hospital Inpatient Prospective Payment System (IPPS) final rule, the Centers for Medicare & Medicaid Services (CMS) created three new coronary IVL-specific MS-DRGs, which will become effective October 1, 2023. These new codes are associated with higher payments than the MS-DRG payments for other Percutaneous Coronary Intervention (PCI) procedures
  • Announced the full commercial availability of the Shockwave C2+ Coronary Intravascular Lithotripsy (IVL) Catheter to treat severely calcified coronary artery disease in select international markets
  • Initiated enrollment in EMPOWER CAD, the first prospective, all-female study of percutaneous coronary intervention, seeking to confirm the benefits of coronary IVL in female patients with calcified lesions, a patient population that historically has experienced less favorable clinical outcomes with traditional therapies compared with male patients
  • Closed the acquisition of Neovasc and commenced the integration into Shockwave

“Our teams throughout the Shockwave organization continue to execute at the highest level, enabling us to offer an expanding range of products to meet the needs of our customers across the globe,” said Doug Godshall, President and Chief Executive Officer of Shockwave Medical. “The consistent growth across our business is a testament to the need for our novel products and we look forward to continuing to provide innovative solutions to improve outcomes for patients suffering from cardiovascular diseases.”

Second Quarter 2023 Financial Results

Revenue for the second quarter ended June 30, 2023, was $180.2 million, a 49% increase from $120.7 million in the same period of 2022. The growth was primarily driven by an increase in the purchase volume of our catheters in both the United States and internationally.

Gross profit for the second quarter of 2023 was $155.7 million compared to $104.0 million for the second quarter of 2022. Gross margin percentage was 86% for the three months ended June 30, 2023, which was unchanged from the gross margin percentage for the three months ended June 30, 2022.

Total operating expenses for the second quarter of 2023 were $123.3 million, a 66% increase from $74.4 million in the second quarter of 2022. The increase was primarily driven by sales force expansion, higher headcount to support the growth of the business, and acquisition-related expenses associated with the acquisition of Neovasc.

Net income for the second quarter of 2023 was $28.9 million, compared to net income of $25.6 million in the same period of 2022. Basic and diluted net income per share for the period was $0.79 and $0.76, respectively.  

Cash, cash equivalents and short-term investments totaled $258.6 million as of June 30, 2023.

2023 Financial Guidance

Shockwave Medical projects revenue for the full year 2023 to range from $725 million to $730 million, which represents 48% to 49% growth over the Company’s prior year revenue. This compares to previous revenue guidance for the full year of 2023 of $700 million to $720 million.

Conference Call

Shockwave Medical will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on Monday, August 7, 2023, to discuss its second quarter 2023 financial results. The call may be accessed by dialing 877-704-4453 for domestic callers or 201-389-0920 for international callers, using conference ID: 13737256. A live and archived webcast of the event will be available at

About Shockwave Medical, Inc. 

Shockwave Medical is a leader in the development and commercialization of innovative products that are transforming the treatment of cardiovascular disease. Its first-of-its-kind Intravascular Lithotripsy (IVL) technology has transformed the treatment of atherosclerotic cardiovascular disease by safely using sonic pressure waves to disrupt challenging calcified plaque, resulting in significantly improved patient outcomes. Shockwave has also recently acquired the Neovasc Reducer, which is under clinical investigation in the United States and is CE Marked in the European Union and the United Kingdom. By redistributing blood flow within the heart, the Reducer is designed to provide relief to the millions of patients worldwide suffering from refractory angina. Learn more at and

Forward-Looking Statements

This press release contains statements relating to our expectations, projections, beliefs, and prospects, which are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue,” and similar expressions, and the negative of these terms. Forward-looking statements in this press release include, but are not limited to, statements regarding our anticipated future operating results and financial position, including for the full year ending December 31, 2023, our business strategy and plans, our objectives for future operations and financial performance and other matters. You are cautioned not to place undue reliance on these forward-looking statements. Forward-looking statements are only predictions based on our current expectations, estimates, and assumptions, valid only as of the date they are made, and subject to risks and uncertainties, some of which we are not currently aware.

Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others: the impact of macroeconomic conditions, including inflation, rising interest rates, the federal budget, instability in the global banking system, and volatile market conditions, geopolitical factors, including the ongoing conflict between Russia and Ukraine and responses thereto, and supply chain disruptions, on our operations, financial results, liquidity, capital resources, expenses, supply chain, manufacturing, research and development activities, clinical trials, and employees; our ability to successfully execute our business and growth strategies; our ability to develop, manufacture, obtain and maintain regulatory approvals for, and market and sell, our products; our expected future growth, including the size and growth potential of the markets for our products; our ability to obtain coverage and reimbursement for procedures performed using our products; our ability to scale our organizational culture; the impact of the development, regulatory approval, efficacy and commercialization of competing products; the loss of key scientific or management personnel; our ability to develop and maintain our corporate infrastructure, including our internal controls; our financial performance and capital requirements; the success of any acquisitions that we make; and our ability to obtain and maintain intellectual property protection for our products, as well as our ability to operate our business without infringing the intellectual property rights of others. These factors, as well as others, are discussed in our filings with the Securities and Exchange Commission (SEC), including in the sections titled “Risk Factors” in our most recent Annual Report on Form 10-K and subsequently filed Quarterly Reports on Form 10-Q, and in our other reports filed with the SEC. Except to the extent required by law, we do not undertake to update any of these forward-looking statements after the date hereof to conform these statements to actual results or revised expectations.

Media Contact:
Scott Shadiow

Investor Contact:
Debbie Kaster

Balance Sheet Data  
(in thousands)  
    June 30,
  December 31,
Cash and cash equivalents   $ 141,458     $ 156,586    
Short-term investments     117,131       147,907    
Accounts receivable, net     96,562       71,366    
Inventory     92,093       75,112    
Prepaid expenses and other current assets     9,118       8,292    
Total current assets     456,362       459,263    
Operating lease right-of-use assets     31,117       32,365    
Property and equipment, net     59,803       48,152    
Equity method investment     2,543       3,512    
Intangible assets, net     94,692          
Goodwill     39,789          
Deferred tax assets     94,699       97,568    
Other assets     7,599       5,229    
TOTAL ASSETS   $ 786,604     $ 646,089    
Accounts payable   $ 12,869     $ 6,721    
Accrued liabilities     65,769       55,375    
Lease liability, current portion     1,582       1,278    
Total current liabilities     80,220       63,374    
Lease liability, noncurrent portion     33,205       34,928    
Debt, noncurrent portion     24,266       24,198    
Related party contract liability, noncurrent portion     12,273       12,273    
Deferred tax liabilities     10,421          
Other liabilities     9,307          
TOTAL LIABILITIES     169,692       134,773    
Preferred stock              
Common stock     37       36    
Additional paid-in capital     586,092       548,960    
Accumulated other comprehensive loss     (391)       (867)    
Retained earnings (accumulated deficit)     31,174       (36,813)    
TOTAL STOCKHOLDERS’ EQUITY     616,912       511,316    

Statement of Operations Data
(in thousands, except share and per share data)
    Three Months Ended   Six Months Ended
    June 30,   June 30,
    2023   2022   2023   2022
Product revenue   $ 180,165     $ 120,746     $ 341,231     $ 214,377  
Cost of revenue:                
Cost of product revenue     24,493       16,730       45,559       29,620  
Gross profit     155,672       104,016       295,672       184,757  
Operating expenses:                
Research and development     36,829       20,760       63,800       37,779  
Sales and marketing     56,738       40,515       110,749       76,476  
General and administrative     29,731       13,165       48,935       25,554  
Total operating expenses     123,298       74,440       223,484       139,809  
Income from operations     32,374       29,576       72,188       44,948  
Loss from equity method investment     (146)       (1,464)       (969)       (1,511)  
Interest expense     (810)       (304)       (1,446)       (601)  
Other income (expense), net     1,586       (1,473)       3,968       (1,783)  
Net income before taxes     33,004       26,335       73,741       41,053  
Income tax provision     4,142       774       5,754       971  
Net income   $ 28,862     $ 25,561     $ 67,987     $ 40,082  
Net income per share, basic   $ 0.79     $ 0.71     $ 1.86     $ 1.12  
Net income per share, diluted   $ 0.76     $ 0.68     $ 1.78     $ 1.06  
Shares used in computing net income per share, basic     36,663,327       35,825,947       36,545,948       35,707,301  
Shares used in computing net income per share, diluted     38,226,153       37,690,094       38,139,948       37,690,320  

Primary Logo

Source: Shockwave Medical, Inc.

Share this page:

Ready to Make Waves with Shockwave Medical?

Looking for careers? Click here.